Bio-Path price target lowered to $2 from $9 at Roth Capital

Roth Capital lowered the firm’s price target on Bio-Path (BPTH) to $2 from $9 and keeps a Buy rating on the shares after the company updated its clinical pipeline progress. Prexigebersen has delivered two complete responses in its Phase 2 AML trial, and the Phase 1 BP0012 trial has seen one cohort 3 patient with a standard deviation and 50% reduction of blast cells, and is now enrolling cohort 4, the analyst tells investors in a research note. The firm noted that liquidity is a concern, which was one reason for the price target decrease.